Introduction: Among patients with acute myeloid leukemia (AML), the DACO-016
with treatment choice (TC): at primary analysis the hazard ratio (HR) was 0.85 (95% confidence interval 0.69-1.04; stratified log-rank P = 0.108). With two interim analyses, two-sided alpha was adjusted to 0.0462. With 1-year additional follow-up the HR reached 0.82 (nominal P = 0.0373). These data resulted in approval of DAC in the European Union, though not in the United States. Though pre-specified, the log-rank test could be considered not optimal to assess the observed survival difference because of the non-proportional hazard nature of the survival curves.
Methods: We applied the Wilcoxon test as a sensitivity analysis. Patients were randomized to DAC (N = 242) or TC (N = 243).
One-hundred and eight (44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively crossed over to subsequent disease modifying therapies at progression, which might impact the survival beyond the median with resultant converging curves (and disproportional hazards).
Results:
The stratified Wilcoxon test showed a significant improvement in median (CI 95%)
overall survival with DAC [7.7 (6.2; 9.2) months] versus TC [5.0 (4.3; 6. 3) months; P = 0.0458].
Conclusion:
Wilcoxon test indicated significant increase in survival for DAC versus TC compared to log-rank test.
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INTRODUCTION
In clinical trials of end-stage or potentially fatal diseases, survival is often the primary outcome measure of efficacy. To get a more granular understanding of underlying mechanisms, survival as one component of overall treatment efficacy is often analyzed by comparing the survival distributions of two or more treatment groups. There are several potential non-parametric and parametric tests available to compare two survival distributions.
Among non-parametric tests based on the ranks of censored survival times, the two classic procedures are the log-rank test and the generalized Wilcoxon procedure. Each of these tests has been shown to be powerful in its ability to detect certain differences between survival distributions [1] . [6, 7] where the pre-specified test, particularly for comparing survival curves, was not the optimal choice once the results were on the table. Since survival curves cannot be predicted and, therefore, the most appropriate test not always pre-specified this need to be discussed and considered in a better way in the future.
Comparing Time-to-Event Distributions
Time-to-event data concern elapsed time until the occurrence of some pre-defined specific event. In simple cases, the event is death (survival), but also other events like progression of a disease, recurrence of disease (progression-free survival), or a complication (e.g., time to first incidence of neuropathy) might be considered. Study participants in principle are at risk for the occurrence of the respective event continuously over time from the beginning of the observation [8] . However, in RCTs the duration of observation may also vary from one subject to another because the subject might withdraw from the study (e.g., due to an adverse drug reaction), the study ends before the subject experiences that event or due to loss of follow-up. This type of censoring is also called ''right censored'' data since times of failure to the right are missing.
The most established way to summarize and compare survival data is calculating survivor functions (or survival curves). Therefore, the Kaplan-Meier estimate is the simplest way of computing the survival over time despite censoring. The Kaplan-Meier survival curve is defined as the probability of surviving in a given length of time while considering time in many small intervals (e.g., day) [9] . Mantel proposed the use of the procedure for combining a series of 2 9 2 tables [10] . In this procedure, each time, t j , a death occurs in either group, a 2 9 2 table is formed. The entry a j represents the observed number of deaths at time t j in the intervention group, and c j represents the observed number of deaths at time t j in the control group (Table 3) . Of the n j participants at risk just prior to time t j , a j ? b j were in the intervention group and c j ? d j were in the control group. The expected number of deaths in the intervention group, denoted as E a j À Á , can be calculated as shown in Fig. 1 Thus, in simpler words, in survival analysis it is possible to obtain different results using different weighting factors depending on where the survival curves separate [11] . If the distribution of the survival curve of the study population is known, a test with an optimal weight function in the weighted log-rank family might be selected before study initiation [11, 12] . However, in practice the shape is unknown and the selection of the weights is problematic as an inappropriate choice may result in a loss of power [13] . However, in real-life practice a choice is often made between versions of the log-rank and the Gehan-Wilcoxon tests [12] .
Log-Rank Test
The log-rank test, proposed by Mantel, is the standard test used in many trials [10] . It has been shown that the log-rank test is the best choice for testing differences, if the so-called proportional hazards assumption holds. This means that the risk for an event (e.g., death) in the intervention group is a constant multiple of the hazard in the control group. The assumption definitely does not hold in case survival curves cross.
Wilcoxon Test
On the other hand, Lee et al. [14] have shown that the Wilcoxon procedure has more power than the log-rank test when the HR is non-constant (proportional hazard assumption must be refused). As indicated above, the Wilcoxon procedure differs from the log-rank test only in that the deviations of observed from expected for both groups are weighted by the number of subjects at risk of failure at each distinct failure time.
Thus, the Wilcoxon test is more sensitive to differences between groups that occur at earlier time points in the conduct of a study (more weights to early events) whereas the log-rank test gives equal weights to all failures regardless to when they occur. As a result, the Wilcoxon test is susceptible to differences in the censoring patterns of the groups.
The HR estimate is routinely used to empirically quantify the between-group difference under the assumption that the ratio of the two hazard functions is approximately constant over time. When the underlying proportional hazards assumption is violated (i.e., the HR is not constant over time) the clinical meaning of such a ratio estimate is difficult, if not impossible, to interpret.
Selective cross-over to subsequent therapies, which is routinely the case in oncology trials, contributes to non-proportional hazards. In this situation a Wilcoxon test can help to interpret the results because it gives more weight to earlier events when no or less subsequent therapy was given. The Cox proportional hazards regression model depends on parametric assumptions. When there is a substantial difference in treatment effect estimates between the covariate-adjusted and unadjusted analyses, concerns about the proportional hazards assumption can arise [15] .
Example of Decitabine
The aforementioned differences between the log-rank and Wilcoxon tests can be quite crucial with regards to the interpretation of results from clinical trials. In light of past decision by the FDA, the RCT for decitabine (DACO-016) in the treatment of AML is used as an illustrative example.
The study showed a non-significant increase in median OS with decitabine (7.7 months; 95% CI 6.2 to 9. These data, together with significant outcomes in secondary endpoints and a Fig. 1 Procedure to calculate the expected number of deaths in the intervention group. The expected number of deaths in the intervention group is denoted E a j À Á . n j participants at risk just prior to time t j , a j ? b j were in the intervention group and c j ? d j were in the control group. The weighting factor w j , which is used for the calculation, determines the test statistic. The test statistics W Although this might be very unlikely, trials could perhaps have been stopped earlier had the appropriate test statistics been the pre-specified statistic of choice [13] . In the absence of clear indications for using the log-rank or Wilcoxon test for the comparison of survival curves legislators might be challenged to specify unambiguous rules if necessary. There is a need in the clinical community to clarify and educate which tests are appropriate when survival curves are non-proportional. It should be possible to ex ante include different test options in a statistical analysis plan making their respective use dependent on the proportionality of hazard rates.
In the future, an adaptively weighted log-rank test might be appropriate because it maintains optimality at the proportional alternatives, while improving the power over a wide range of non-proportional alternatives [14] . Uno et al. [15] suggest that when there is not sufficient information about the profile of the between-group difference at the design stage of the study, practitioners should consider a pre-specified, clinically meaningful, model-free measure for quantifying the difference and to use robust estimation procedures to draw primary inferences.
